Why the study?
Are mutations in the transcriptional activator domain of TBX20 associated with atrial septal defect or ventricular septal defect?
Are mutations in the transcriptional activator domain of TBX20 associated with atrial septal defect or ventricular septal defect?
This study identifies the first association of TBX20 transcriptional activator domain missense mutations with atrial septal defect, which may have implications for genetic screening.
Answers are grounded in this paper and cite their sources.
TBX20 activator domain mutations may contribute to ASD; hypothesis-generating for genetic screening and requires prospective validation before clinical adoption.
BACKGROUND: The relevance of TBX20 gene in heart development has been demonstrated in many animal models, but there are few works that try to elucidate the effect of TBX20 mutations in human congenital heart diseases. In these studies, all missense mutations associated with atrial septal defect (ASD) were found in the DNA-binding T-box domain, none in the transcriptional activator domain. METHODS: We search for TBX20 mutations in a group of patients with ASD or ventricular septal defect (VSD) using the High Resolution Melting (HRM) method and DNA sequencing. RESULTS: We report three missense mutations (Y309D, T370O, and M395R) within the transcriptional activator domain of human TBX20 that were associated with ASD. CONCLUSIONS: This is the first association of TBX20 transcriptional activator domain missense mutations with ASD. These findings could have implications for diagnosis, genetic screening, and patient follow-up.
No takes yet. Share an insight, caveat, or question.
Monroy-Muñoz et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: